X4 Pharmaceuticals Inc (XFOR) Receives Average Recommendation of “Buy” from Brokerages

X4 Pharmaceuticals Inc (NASDAQ:XFOR) has been assigned an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company. X4 Pharmaceuticals’ rating score has improved by 33.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a one year consensus target price of $19.50 for the company, according to Zacks. Zacks has also given X4 Pharmaceuticals an industry rank of 79 out of 256 based on the ratings given to related companies.

Separately, Canaccord Genuity started coverage on X4 Pharmaceuticals in a research report on Tuesday, May 21st. They issued a “buy” rating and a $27.00 target price for the company.

Shares of X4 Pharmaceuticals stock opened at $17.17 on Tuesday. X4 Pharmaceuticals has a twelve month low of $6.90 and a twelve month high of $114.00. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.57.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($6.67) earnings per share (EPS) for the quarter.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Further Reading: 52-Week High/Low

Get a free copy of the Zacks research report on X4 Pharmaceuticals (XFOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.